Pharmacokinetics of a Novel Endectoparasiticide Topical Formulation for Cats, Combining Esafoxolaner, Eprinomectin and Praziquantel

Overview

Journal Parasite

Specialty Parasitology

Date 2021 Apr 4

PMID 33812451

Citations 8

Authors

Virginie Jacquot

Prescillia Buellet

Laura Letendre

Wei Tong

Henry Li

Eric Tielemans

Affiliations

Soon will be listed here.

Abstract

Esafoxolaner, a purified enantiomer of afoxolaner with insecticidal and acaricidal properties, is combined with eprinomectin and praziquantel in NexGard Combo, a novel topical endectoparasiticide formulation for cats. The parasiticide potencies of topical esafoxolaner, eprinomectin and praziquantel, are based on transcutaneous absorption, systemic distribution, and exposure of respective target parasites. For each compound, the pharmacokinetic profile, non-interference, dose linearity/proportionality after one administration, and the accumulation and time to reach a steady state after repeated monthly administrations of the novel formulation, were investigated. After one topical application of NexGard Combo at the minimum recommended dose, the mean plasma concentration of esafoxolaner immediately reached (and remained at) a level supporting rapid onset and sustained efficacy against ectoparasites for at least 1 month. The mean C, T, T, and the topical bioavailability of esafoxolaner were 130 ng/mL, 7.1 days, 21.7 days and 47.2%, respectively, and the plasma profiles of eprinomectin and praziquantel supported their known endoparasiticide properties. No relevant interference between the three compounds was observed. Dose proportionality was demonstrated for the three compounds over a range of 0.5× to 2× the minimum recommended dose. Steady state after repeated monthly administrations was reached by the second dose for praziquantel and by the fifth dose for esafoxolaner and eprinomectin. Accumulation was limited and drug plasma concentrations were maintained within a safe level.

Citing Articles

Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats.

Mencke N, Baumer W, Fraatz K, Krebber R, Schneider M, Blazejak K Curr Res Parasitol Vector Borne Dis. 2023; 4:100126.

PMID: 37456557 PMC: 10344656. DOI: 10.1016/j.crpvbd.2023.100126.

Efficacy of a topical product combining esafoxolaner, eprinomectin and praziquantel against bedbug (Cimex lectularius) experimental infestations in cats.

Tielemans E, Rautenbach C, Besselaar J, Beugnet F Parasite. 2022; 29:59.

PMID: 36562440 PMC: 9879142. DOI: 10.1051/parasite/2022060.

Efficacy of a topical formulation containing esafoxolaner, eprinomectin and praziquantel (NexGard Combo) against natural infestations with the cat louse, Felicola subrostratus under field conditions.

Mihalca A, Deak G, Panait L, Rabei S, Beugnet F Parasite. 2022; 29:62.

PMID: 36562429 PMC: 9879157. DOI: 10.1051/parasite/2022062.

Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for the prevention of heartworm disease in cats.

Baker C, McCall J, Mansour A, McCall S, Shaffer T, Wakeland K Parasite. 2021; 28:30.

PMID: 33812462 PMC: 8019556. DOI: 10.1051/parasite/2021026.

Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against Echinococcus multilocularis infections in cats.

Prullage J, Bowman D, Ulrich M, Tielemans E Parasite. 2021; 28:29.

PMID: 33812461 PMC: 8019559. DOI: 10.1051/parasite/2021025.

References

Tielemans E, Pfefferkorn A, Viljoen A . Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against Rhipicephalus sanguineus in cats. Parasite. 2021; 28:24. PMC: 8019555. DOI: 10.1051/parasite/2021020. View

Hampel V, Knaus M, Schafer J, Beugnet F, Rehbein S . Treatment of canine sarcoptic mange with afoxolaner (NexGard) and afoxolaner plus milbemycin oxime (NexGard Spectra) chewable tablets: efficacy under field conditions in Portugal and Germany. Parasite. 2018; 25:63. PMC: 6280674. DOI: 10.1051/parasite/2018064. View

Soll M, Kunkle B, Royer G, Yazwinski T, Baggott D, Wehner T . An eprinomectin extended-release injection formulation providing nematode control in cattle for up to 150 days. Vet Parasitol. 2013; 192(4):313-20. DOI: 10.1016/j.vetpar.2012.11.037. View

Traversa D . Pet roundworms and hookworms: a continuing need for global worming. Parasit Vectors. 2012; 5:91. PMC: 3418564. DOI: 10.1186/1756-3305-5-91. View

Ozoe Y, Asahi M, Ozoe F, Nakahira K, Mita T . The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels. Biochem Biophys Res Commun. 2009; 391(1):744-9. DOI: 10.1016/j.bbrc.2009.11.131. View

Schroeder I, Altreuther G, Schimmel A, Deplazes P, Kok D, Schnyder M . Efficacy of emodepside plus praziquantel tablets (Profender tablets for dogs) against mature and immature cestode infections in dogs. Parasitol Res. 2009; 105 Suppl 1:S31-8. DOI: 10.1007/s00436-009-1493-y. View

Lucio-Forster A, Bowman D . Prevalence of fecal-borne parasites detected by centrifugal flotation in feline samples from two shelters in upstate New York. J Feline Med Surg. 2011; 13(4):300-3. PMC: 10832825. DOI: 10.1016/j.jfms.2010.12.013. View

Machado M, Campos D, Lopes N, Bastos I, Botelho C, Correia T . Efficacy of afoxolaner in the treatment of otodectic mange in naturally infested cats. Vet Parasitol. 2018; 256:29-31. DOI: 10.1016/j.vetpar.2018.04.013. View

Charles S, Altreuther G, Reinemeyer C, Buch J, Settje T, Cruthers L . Evaluation of the efficacy of emodepside+praziquantel topical solution against cestode (Dipylidium caninum, Taenia taeniaeformis, and Echinococcus multilocularis) infections in cats. Parasitol Res. 2005; 97 Suppl 1:S33-S40. DOI: 10.1007/s00436-005-1442-3. View

10.

Kunkle B, Daly S, Dumont P, Drag M, Larsen D . Assessment of the efficacy of orally administered afoxolaner against Rhipicephalus sanguineus sensu lato. Vet Parasitol. 2014; 201(3-4):226-8. DOI: 10.1016/j.vetpar.2014.02.018. View

11.

Kvaternick V, Kellermann M, Knaus M, Rehbein S, Rosentel J . Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. Vet Parasitol. 2014; 202(1-2):2-9. DOI: 10.1016/j.vetpar.2014.02.031. View

12.

Mitchell E, McCall J, Chester S, Larsen D . Efficacy of afoxolaner against Ixodes scapularis ticks in dogs. Vet Parasitol. 2014; 201(3-4):223-5. DOI: 10.1016/j.vetpar.2014.02.015. View

13.

Gupta A, Baker C, Wang H, Targa N, Pfefferkorn A, Tielemans E . Target animal safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for cats. Parasite. 2021; 28:18. PMC: 8019570. DOI: 10.1051/parasite/2021015. View

14.

Letendre L, Harriman J, Drag M, Mullins A, Malinski T, Rehbein S . The intravenous and oral pharmacokinetics of afoxolaner and milbemycin oxime when used as a combination chewable parasiticide for dogs. J Vet Pharmacol Ther. 2016; 40(1):35-43. DOI: 10.1111/jvp.12332. View

15.

Tielemans E, Otsuki T, Cheesman T, Selmes F, Pfefferkorn A, Prullage J . Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions. Parasite. 2021; 28:22. PMC: 8019569. DOI: 10.1051/parasite/2021018. View

16.

Letendre L, Huang R, Kvaternick V, Harriman J, Drag M, Soll M . The intravenous and oral pharmacokinetics of afoxolaner used as a monthly chewable antiparasitic for dogs. Vet Parasitol. 2014; 201(3-4):190-7. DOI: 10.1016/j.vetpar.2014.02.021. View

17.

Tielemans E, Manavella C, Visser M, Chester S, Rosentel J . Efficacy in cats of a novel topical combination of fipronil, (S)-methoprene, eprinomectin, praziquantel, against induced infestations of Echinococcus multilocularis. Vet Parasitol. 2014; 202(1-2):26-9. DOI: 10.1016/j.vetpar.2014.02.034. View

18.

Knaus M, Abu-Madi M, Ibarra-Velarde F, Kok D, Kusi I, Postoli R . Efficacy of a novel topical fipronil, (S)-methoprene, eprinomectin and praziquantel combination against naturally acquired intestinal nematode and cestode infections in cats. Vet Parasitol. 2014; 202(1-2):18-25. DOI: 10.1016/j.vetpar.2014.02.033. View

19.

Beugnet F, Bourdeau P, Chalvet-Monfray K, Cozma V, Farkas R, Guillot J . Parasites of domestic owned cats in Europe: co-infestations and risk factors. Parasit Vectors. 2014; 7:291. PMC: 4082530. DOI: 10.1186/1756-3305-7-291. View

20.

Woods D, Vaillancourt V, Wendt J, Meeus P . Discovery and development of veterinary antiparasitic drugs: past, present and future. Future Med Chem. 2011; 3(7):887-96. DOI: 10.4155/fmc.11.39. View